An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal.
Connor EnrightElizabeth ThomasDavid R SaxonPublished in: Journal of the Endocrine Society (2023)
Despite professional society guidelines recommending that obesity be treated as a chronic disease by emphasizing the use of lifestyle modification in conjunction with pharmacotherapy, antiobesity medications are uncommonly prescribed in most clinical practices. The recent Food and Drug Administration approval of semaglutide 2.4 mg weekly to treat obesity-as well as other forthcoming advancements in diabetes and antiobesity medications-highlights the potential of pharmacotherapy to significantly augment weight loss efforts. In this Expert Endocrine Consult, we review the evolving role of antiobesity pharmacotherapy in clinical practice and suggest a framework for the use of these medications.
Keyphrases
- weight loss
- clinical practice
- bariatric surgery
- drug administration
- roux en y gastric bypass
- smoking cessation
- glycemic control
- gastric bypass
- metabolic syndrome
- type diabetes
- weight gain
- cardiovascular disease
- insulin resistance
- primary care
- healthcare
- human health
- obese patients
- risk assessment
- quality improvement
- climate change
- body mass index